Switching intravenous to subcutaneous infliximab was safe and successful during 1-year follow up in Ulcerative Colitis and Crohn patients - a Belgian single center experience.

Background: Subcutaneous (SC) infliximab CT-P13 (IFX) has recently been registered for the treatment of moderate-to-severe inflammatory bowel disease (IBD). The SC route is an attractive option for patients. However, many open questions remain on how to safely switch patients from maintenance IV to SC administration.